Skip to main content
. 2024 Dec 18;24:905. doi: 10.1186/s12888-024-06346-2

Table 3.

Comparisons of demographic and clinical variables among groups (recurrence vs. fluctuation vs. maintenance)

Variables Recurrence (n = 16) Fluctuation (n = 7) Maintenance
(n = 12)
Statistic
N (%) N(%) N (%) χ2 p
Male a 4(35.0%) 2(28.6%) 6(50.0%) 1.982 0.424
Psychotic symptoms 2(12.5%) 0(0.0%) 3(25.0%) 1.895 0.477
Drinking a 2(12.5%) 0(0.0%) 0(0.0%) 1.720 0.677
Experience of child-parent separation 11(68.8%) 3(42.9%) 7(58.3%) 1.436 0.492
Treatment regimens 4.353 0.369
aiTBS 4(25.0%) 3(42.9%) 1(8.3%)
iTBS 4(25.0%) 1(14.3%) 6(50.0%)
Sham 8(50.0%) 3(42.9%) 5(41.7%)
Antidepressanta 11(68.8%) 6(85.7%) 7(58.3%) 1.439 0.507
Antipsychotic 6(37.5%) 2(28.6%) 2(16.7%) 1.466 0.561
Benzodiazepine 6(37.5%) 4(57.1%) 1(8.3%) 5.387 0.079
Mean ± SD Mean ± SD Mean ± SD F/χ2 p
Age (years) 14.56 ± 1.97 15.00 ± 2.00 17.33 ± 3.20 4.587 0.012
Education (years) 9.06 ± 1.84 9.29 ± 2.43 11.08 ± 2.61 3.008 0.064
Disease duration (months) b 20.94 ± 14.04 20.43 ± 16.29 29.33 ± 43.46 0.154 0.926
MT(%) 54.06 ± 3.97 55.57 ± 2.44 51.67 ± 5.30 2.074 0.142

Fluoxetine equivalent

(mg/day) b

44.28 ± 83.16 21.43 ± 49.72 11.11 ± 29.59 1.588 0.452
Chlorpromazine equivalent (mg/day) b 18.01 ± 16.30 17.90 ± 12.93 11.48 ± 10.34 1.402 0.496
HAMD-17 23.38 ± 5.60 24.86 ± 5.94 22.61 ± 6.21 0.359 0.701
HAMA 23.57 ± 8.65 21.71 ± 6.85 21.50 ± 6.30 0.701 0.503
GAF 47.50 ± 9.31 50.71 ± 5.36 49.17 ± 6.69 0.441 0.648
NSSI-behaviorb 11.00 ± 8.76 6.44 ± 3.71 7.97 ± 7.93 1.470 0.479
NSSI-function b 30.56 ± 15.39 22.68 ± 9.73 27.96 ± 11.02 2.024 0.364

Abbreviations: aiTBS accelerated intermittent Theta Burst Stimulation, MT Motor Threshold, HAMD-17 17-item Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale, GAF Global Assessment of Function, NSSI Non-suicidal Self-Injury

aFisher exact test

bKruskal-Wallis test